Table of Content

1 INTRODUCTION
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders
4.2.2 Rising Research & Development Activities of Generic Drugs
4.2.3 Increasing Adoption of Biologicals and Biosimilars
4.3 Market Restraints
4.3.1 Drug Price Control Policies
4.3.2 Stringent Regulations and Drug Price Policies in the Country
4.4 Industry Attractiveness - Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Business Mode
5.1.1 Captive API
5.1.2 Merchant API
5.2 By Synthesis Type
5.2.1 Synthetic
5.2.2 Biotech
5.3 By Drug Type
5.3.1 Generic
5.3.2 Branded
5.4 By Application
5.4.1 Cardiology
5.4.2 Oncology
5.4.3 Pulmonology
5.4.4 Neurology
5.4.5 Orthopedic
5.4.6 Ophthalmology
5.4.7 Other Applications


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aurobindo Pharma
6.1.2 Pfizer Inc.
6.1.3 Novartis AG
6.1.4 BASF SE
6.1.5 Boehringer Ingelheim GmbH
6.1.6 Viatris Inc.
6.1.7 Sanofi Inc.
6.1.8 GlaxoSmithKline PLC
6.1.9 Dr. Reddy’s Laboratories Ltd
6.1.10 Lupin Ltd
6.1.11 Sun Pharmaceutical Industries Ltd


7 MARKET OPPORTUNITIES AND FUTURE TRENDS